ENDRA Life Sciences Inc. (NDRA)
USD 3.61
(-8.61%)
USD 3.61
(-8.61%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -2.43 Million USD | 43.82% |
| 2022 | -4.34 Million USD | 50.56% |
| 2021 | -8.78 Million USD | -34.25% |
| 2020 | -6.54 Million USD | -19.66% |
| 2019 | -5.46 Million USD | 15.52% |
| 2018 | -6.47 Million USD | -15.52% |
| 2017 | -5.6 Million USD | -795.87% |
| 2016 | 805.02 Thousand USD | 4308.61% |
| 2015 | -19.12 Thousand USD | 87.77% |
| 2014 | -156.44 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -6.11 Million USD | -654.91% |
| 2024 Q1 | -810.63 Thousand USD | 66.77% |
| 2023 Q3 | -2.9 Million USD | 33.28% |
| 2023 FY | -2.43 Million USD | 43.82% |
| 2023 Q4 | -2.43 Million USD | 15.89% |
| 2023 Q2 | -4.34 Million USD | -135.58% |
| 2023 Q1 | -1.84 Million USD | 57.51% |
| 2022 Q3 | -7.43 Million USD | 30.27% |
| 2022 FY | -4.34 Million USD | 50.56% |
| 2022 Q4 | -4.34 Million USD | 41.59% |
| 2022 Q2 | -10.66 Million USD | -64.55% |
| 2022 Q1 | -6.48 Million USD | 26.22% |
| 2021 Q2 | -13.3 Million USD | 19.28% |
| 2021 Q1 | -16.48 Million USD | -151.96% |
| 2021 Q4 | -8.78 Million USD | 20.76% |
| 2021 FY | -8.78 Million USD | -34.25% |
| 2021 Q3 | -11.08 Million USD | 16.69% |
| 2020 Q4 | -6.54 Million USD | -111.57% |
| 2020 Q2 | -32.02 Thousand USD | 98.8% |
| 2020 Q1 | -2.66 Million USD | 51.16% |
| 2020 FY | -6.54 Million USD | -19.66% |
| 2020 Q3 | -3.09 Million USD | -9554.95% |
| 2019 Q4 | -5.46 Million USD | -333.53% |
| 2019 Q3 | -1.26 Million USD | 44.39% |
| 2019 Q2 | -2.26 Million USD | 42.24% |
| 2019 Q1 | -3.92 Million USD | 39.34% |
| 2019 FY | -5.46 Million USD | 15.52% |
| 2018 Q1 | -3.14 Million USD | 43.77% |
| 2018 Q4 | -6.47 Million USD | -14786.59% |
| 2018 Q2 | -1.85 Million USD | 41.2% |
| 2018 Q3 | 44.06 Thousand USD | 102.38% |
| 2018 FY | -6.47 Million USD | -15.52% |
| 2017 Q3 | -6.97 Million USD | 7.26% |
| 2017 Q1 | 1.16 Million USD | 45.09% |
| 2017 FY | -5.6 Million USD | -795.87% |
| 2017 Q4 | -5.6 Million USD | 19.71% |
| 2017 Q2 | -7.52 Million USD | -744.17% |
| 2016 Q2 | -238.42 Thousand USD | -1346.47% |
| 2016 FY | 805.02 Thousand USD | 4308.61% |
| 2016 Q4 | 805.02 Thousand USD | 65.55% |
| 2016 Q3 | 486.26 Thousand USD | 303.95% |
| 2016 Q1 | 19.12 Thousand USD | 200.0% |
| 2015 Q4 | -19.12 Thousand USD | 0.0% |
| 2015 Q1 | 156.44 Thousand USD | 0.0% |
| 2015 FY | -19.12 Thousand USD | 87.77% |
| 2014 FY | -156.44 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -39.45 Million USD | 93.817% |
| Applied DNA Sciences, Inc. | -5.91 Million USD | 58.751% |
| Aspira Women's Health Inc. | -331 Thousand USD | -637.01% |
| Biodesix, Inc. | 34.3 Million USD | 107.111% |
| BioNexus Gene Lab Corp. | -5.79 Million USD | 57.91% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | -96.27% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | -96.27% |
| Bionano Genomics, Inc. | 34.88 Million USD | 106.994% |
| CareDx, Inc | -47.97 Million USD | 94.915% |
| Check-Cap Ltd. | -24.75 Million USD | 90.146% |
| Castle Biosciences, Inc. | -83.53 Million USD | 97.08% |
| DarioHealth Corp. | -7.54 Million USD | 67.68% |
| Exact Sciences Corporation | 1.94 Billion USD | 100.125% |
| Fulgent Genetics, Inc. | -82.56 Million USD | 97.045% |
| Guardant Health, Inc. | 220.22 Million USD | 101.108% |
| ICON Public Limited Company | 3.56 Billion USD | 100.069% |
| IDEXX Laboratories, Inc. | 493.94 Million USD | 100.494% |
| Illumina, Inc. | 1.21 Billion USD | 100.201% |
| Intelligent Bio Solutions Inc. | -5.43 Million USD | 55.096% |
| iSpecimen Inc. | -2.14 Million USD | -13.602% |
| Standard BioTools Inc. | 46.5 Million USD | 105.246% |
| MDxHealth SA | 18.88 Million USD | 112.918% |
| 23andMe Holding Co. | -141.37 Million USD | 98.274% |
| Medpace Holdings, Inc. | -103.32 Million USD | 97.639% |
| Myriad Genetics, Inc. | 88.1 Million USD | 102.769% |
| Mainz Biomed B.V. | 349.85 Thousand USD | 797.29% |
| NeoGenomics, Inc. | 269.19 Million USD | 100.906% |
| Neogen Corporation | 735.62 Million USD | 100.332% |
| Inotiv, Inc. | 382.14 Million USD | 100.638% |
| Natera, Inc. | -200.1 Million USD | 98.781% |
| OpGen, Inc. | 11.89 Million USD | 120.514% |
| OPKO Health, Inc. | 230.68 Million USD | 101.058% |
| Psychemedics Corporation | 334 Thousand USD | 830.39% |
| Prenetics Global Limited | -43.33 Million USD | 94.371% |
| Prenetics Global Limited | -43.33 Million USD | 94.371% |
| Precipio, Inc. | -386 Thousand USD | -531.996% |
| Personalis, Inc. | -8.02 Million USD | 69.59% |
| RadNet, Inc. | 1.14 Billion USD | 100.212% |
| Sera Prognostics, Inc. | -2.02 Million USD | -20.648% |
| Sotera Health Company | 2.02 Billion USD | 100.12% |
| Neuronetics, Inc. | 2.79 Million USD | 187.219% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 84.094% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 84.094% |
| Trinity Biotech plc | 63.73 Million USD | 103.828% |
| T2 Biosystems, Inc. | 33.8 Million USD | 107.216% |
| Twist Bioscience Corporation | -192.4 Million USD | 98.732% |
| Exagen Inc. | -12.77 Million USD | 80.9% |